Most Read Articles
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Roshini Claire Anthony, 5 days ago

A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.

Roshini Claire Anthony, 3 days ago

The use of intramuscular depot medroxyprogesterone acetate (DMPA-IM) did not increase a woman’s risk of acquiring HIV compared with the use of a copper intrauterine device (IUD) or a levonorgestrel implant, results of a study conducted by the ECHO* Trial Consortium show.

14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).

Abrilumab effective for ulcerative colitis

23 Mar 2019

The monoclonal antibody abrilumab is effective for treating moderate-to-severe ulcerative colitis, promoting remission, clinical response and mucosal healing, a recent study has found.

Researchers randomly assigned 354 ulcerative colitis patients with inadequate responses to conventional therapies to receive abrilumab 7 mg every 4 weeks (n=21), 21 mg every 4 weeks (n=40), 70 mg every 4 weeks (n=98) or 210 mg at day 1 (n=79); or placebo (n=116). Study endpoints included remission, response and mucosal healing.

The unadjusted remission rates at 8 weeks were 4.3 percent, 0.0 percent, 2.5 percent, 13.3 percent and 12.7 percent for the placebo, 7-mg, 21-mg, 70-mg and 210-mg groups, respectively. Patients who received the two highest abrilumab doses were significantly likely to achieve remission than those who were given placebo (70 mg: odds ratio [OR], 3.35; 95 percent CI, 1.41–7.95; p=0.021; 210 mg: OR, 3.33; 1.34–8.26; p=0.030).

Unadjusted response rates at 8 weeks for the placebo, 7-mg, 21-mg, 70-mg and 210-mg groups were 25.9 percent, 14.3 percent, 50.0 percent, 49.0 percent and 46.8 percent, respectively.

Similarly, those given the highest two abrilumab doses were significantly more likely to achieve response at 8 weeks (70 mg: OR, 2.78; 1.71–4.52; p<0.001; 210 mg: OR, 2.57; 1.53–4.51; p=0.003).

The same was true for mucosal healing (70 mg: OR, 2.34; 1.35–4.07; p=0.011; 210 mg: OR, 2.10; 1.15–3.82; p=0.041). The corresponding unadjusted mucosal healing rates at 8 weeks were 21.6 percent, 14.3 percent, 15.0 percent, 32.7 percent and 29.1 percent for the placebo, 7-mg, 21-mg, 70-mg and 210-mg groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Roshini Claire Anthony, 5 days ago

A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.

Roshini Claire Anthony, 3 days ago

The use of intramuscular depot medroxyprogesterone acetate (DMPA-IM) did not increase a woman’s risk of acquiring HIV compared with the use of a copper intrauterine device (IUD) or a levonorgestrel implant, results of a study conducted by the ECHO* Trial Consortium show.

14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).